Who
Joshua Lehrer-Graiwer
Director
Company insider
Files Form 4 as: Director, Fulcrum Therapeutics; President and CEO, LENZ Therapeutics; Chief Medical Officer, Global Blood Therapeutics.
In numbers
- Trades disclosed
- 97
- Buys
- 0
- Sells
- 14
- Bought
- $0
- Sold
- $3.3M
- Companies
- 3
- Companies where not an officer
- 1
- First trade
- 1 Oct 2019
- Last trade
- 23 Apr 2026
- Last filed
- 1 May 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 23 Apr 2026filed 1 May 2026 | FULC Fulcrum Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —64,000 at $0.00 | filing |
| 23 Apr 2026filed 1 May 2026 | FULC Fulcrum Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —64,000 at $0.00 | filing |
| 21 Feb 2023filed 23 Feb 2023 | LENZ LENZ Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —600,000 at $0.00 | filing |
| 16 Feb 2022filed 18 Feb 2022 | LENZ LENZ Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —650,000 at $0.00 | filing |
| 29 Jun 2021filed 1 Jul 2021 | LENZ LENZ TherapeuticsBiotechnology | SEC FORM 4 Code C | —8,126 | filing |
| 29 Jun 2021filed 1 Jul 2021 | LENZ LENZ Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code C | —19,763 at $0.00 | filing |
| 17 Mar 2021filed 1 Jul 2021 | LENZ LENZ Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —795,196 at $0.00 | filing |
| 17 Mar 2021filed 1 Jul 2021 | LENZ LENZ Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —340,798 at $0.00 | filing |
| 11 Mar 2021filed 1 Jul 2021 | LENZ LENZ Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | $100K19,763 at $5.06 | filing |
| 16 Jan 2021filed 1 Jul 2021 | LENZ LENZ TherapeuticsBiotechnology | SEC FORM 4 Code M | $112K374,013 at $0.30 | filing |
| 16 Jan 2021filed 1 Jul 2021 | LENZ LENZ Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —374,013 at $0.00 | filing |
| 13 Jan 2021filed 1 Jul 2021 | LENZ LENZ Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —374,013 at $0.00 | filing |
| 9 Mar 2020filed 9 Mar 2020 | Global Blood Therapeuticsoption or derivative | SEC FORM 4 Code M | —938 at $0.00 | filing |
| 9 Mar 2020filed 9 Mar 2020 | Global Blood Therapeutics | SEC FORM 4 Code M | $19K938 at $19.89 | filing |
| 9 Mar 2020filed 9 Mar 2020 | Global Blood Therapeutics | SEC FORM 4 Sold | $56K938 at $59.90 | filing |
| 5 Mar 2020filed 9 Mar 2020 | Global Blood Therapeutics | SEC FORM 4 Sold | $74K1,138 at $65.30 | filing |
| 1 Mar 2020filed 4 Mar 2020 | Global Blood Therapeuticsoption or derivative | SEC FORM 4 Code M | —1,750 at $0.00 | filing |
| 1 Mar 2020filed 4 Mar 2020 | Global Blood Therapeutics | SEC FORM 4 Code M | —1,750 | filing |
| 1 Mar 2020filed 4 Mar 2020 | Global Blood Therapeutics | SEC FORM 4 Code F | $39K612 at $63.96 | filing |
| 18 Feb 2020filed 20 Feb 2020 | Global Blood Therapeuticsoption or derivative | SEC FORM 4 Code M | —1,313 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.